Celadon Pharmaceuticals PLC (CEL) — Strategic Asset Allocation Index
Celadon Pharmaceuticals PLC (CEL) has a Strategic Asset Allocation Index of 206.8% as of June 2023. Strategic assets (PP&E of GBX6.27 Million plus long-term investments of GBX-) total GBX6.27 Million, measured against net assets of GBX3.03 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See CEL equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Celadon Pharmaceuticals PLC Strategic Asset Allocation Index (2020–2022)
This chart shows how Celadon Pharmaceuticals PLC's Strategic Asset Allocation Index has evolved across 2 annual periods from 2020 to 2022. As of June 2023, the index stands at 206.8%, representing strategic assets of GBX6.27 Million against net assets of GBX3.03 Million GBX. For live market cap and overall valuation, see CEL stock market capitalisation.
Annual Strategic Asset Allocation Index for Celadon Pharmaceuticals PLC (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Celadon Pharmaceuticals PLC from 2020 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See CEL net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 89.2% | GBX6.28 Million | GBX6.28 Million | GBX- | GBX7.04 Million | ▼ -2974.0 pp |
| 2020 | 3063.1% | GBX3.03 Million | GBX3.03 Million | GBX- | GBX99.03K | — |